Start for free
Start for free
PB

Paradigm BioCapital Advisors

North America, New York, United States, New York

Description

Paradigm BioCapital Advisors is an investment firm.

Investor Profile

Paradigm BioCapital Advisors has made 13 investments, with 7 in the past 12 months and 8% as lead.

Stage Focus

  • Post Ipo Equity (69%)
  • Series C (23%)
  • Undisclosed (8%)

Country Focus

  • United States (77%)
  • United Kingdom (8%)
  • Canada (8%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
  • Biopharma
  • Oncology
  • Medical Device
  • Clinical Trials
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Paradigm BioCapital Advisors frequently co-invest with?

Wellington Management
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Surveyor Capital
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 5
Adage Capital Management
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Braidwell
Braidwell
North America, Connecticut, United States, Stamford
Co-Investments: 5
RTW Investments
RTW Investments
North America, New York, United States, New York
Co-Investments: 4
TCG Crossover
TCG Crossover
North America, California, United States, Palo Alto
Co-Investments: 4
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 5
Deep Track Capital
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 7
Logos Capital
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 7
Janus Henderson Investors
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 6

What are some of recent deals done by Paradigm BioCapital Advisors?

Olema Oncology

San Francisco, California, United States

Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.

BiopharmaBiotechnologyHealth CareMedicalOncologyPharmaceutical
Post Ipo EquityDec 2, 2024
Amount Raised: $250,000,000
35Pharma

Montreal, Quebec, Canada

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

BiopharmaBiotechnologyPharmaceutical
Series CNov 26, 2024
Amount Raised: $53,000,000

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

BiotechnologyHealth CareMedical Device
UndisclosedOct 29, 2024
Amount Raised: $200,000,000
Oruka Therapeutics

Waltham, Massachusetts, United States

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

BiotechnologyHealth CareMedical
Post Ipo EquitySep 3, 2024
Amount Raised: $275,000,000
Elektrofi

Boston, Massachusetts, United States

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative MedicineBiotechnologyTherapeutics
Series CAug 22, 2024
Amount Raised: $112,250,000
Disc Medicine

Watertown, Massachusetts, United States

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityJun 14, 2024
Amount Raised: $178,000,000
Cullinan Therapeutics

Cambridge, Massachusetts, United States

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

BiopharmaBiotechnologyMedical DeviceOncology
Post Ipo EquityApr 16, 2024
Amount Raised: $280,000,000
Acrivon Therapeutics

Cambridge, Massachusetts, United States

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

BiotechnologyHealth CareOncologyTherapeutics
Post Ipo EquityApr 9, 2024
Amount Raised: $130,000,000
Obsidian Therapeutics

Cambridge, Massachusetts, United States

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

BiotechnologyHealth CarePharmaceutical
Series CApr 3, 2024
Amount Raised: $160,500,000
Crinetics Pharmaceuticals

San Diego, California, United States

Crinetics is a clinical-stage pharmaceutical company that develops therapies for people with rare endocrine diseases.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityFeb 28, 2024
Amount Raised: $350,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator